BioVentrix
BioVentrix offers innovative treatment options for heart failure patients, including the Revivent TC Transcatheter Ventricular Enhancement System, and is headquartered in Mansfield, MA, USA.
Services
BioVentrix offers a novel treatment option for patients suffering from heart failure. The company specializes in providing solutions designed to improve cardiac function by restoring the shape, volume, and performance of the left ventricle in ischemic heart failure patients. This is achieved through their innovative Revivent TC Transcatheter Ventricular Enhancement System and the LIVE Procedure, which utilizes a closed-chest, catheter-based technique to remodel the left ventricle.
Products
The primary product offered by BioVentrix is the Revivent TC Transcatheter Ventricular Enhancement System. This system is aimed at enhancing cardiac function by restoring the optimal shape of the left ventricle. It aids in reducing the volume of the ventricle and improving its performance in patients suffering from ischemic heart failure. This innovative approach seeks to provide a viable alternative to more invasive surgical methods for treating heart failure.
Clinical Studies
BioVentrix is actively involved in conducting the ALIVE clinical study for the treatment of symptomatic heart failure patients in the United States. This prospective, multi-center, dual-arm pivotal study began enrolling patients in July 2017. The study aims to assess the efficacy and safety of the company's therapies in improving the condition of patients suffering from heart failure.
Funding
BioVentrix has successfully secured $48.5 million in Series A financing. This funding supports the further development and commercialization of the company's innovative heart failure treatment solutions. By raising substantial financing, BioVentrix emphasizes its commitment to advancing medical treatments for heart failure patients.
Headquarters
BioVentrix is headquartered in Mansfield, Massachusetts, USA. From this location, the company manages its operations, research, and development efforts aimed at providing effective treatment solutions for heart failure patients globally.
